174 related articles for article (PubMed ID: 22172290)
21. Utility of pharmacodynamic measures for assessing the oral bioavailability of peptides. 1. Administration of recombinant salmon calcitonin in rats.
Sinko PJ; Smith CL; McWhorter LT; Stern W; Wagner E; Gilligan JP
J Pharm Sci; 1995 Nov; 84(11):1374-8. PubMed ID: 8587058
[TBL] [Abstract][Full Text] [Related]
22. Coating formulations for microneedles.
Gill HS; Prausnitz MR
Pharm Res; 2007 Jul; 24(7):1369-80. PubMed ID: 17385011
[TBL] [Abstract][Full Text] [Related]
23. Flash Fabrication of Orally Targeted Nanocomplexes for Improved Transport of Salmon Calcitonin across the Intestine.
Sun L; Le Z; He S; Liu J; Liu L; Leong KW; Mao HQ; Liu Z; Chen Y
Mol Pharm; 2020 Mar; 17(3):757-768. PubMed ID: 32011888
[TBL] [Abstract][Full Text] [Related]
24. Design and evaluation of poly(DL-lactic-co-glycolic acid) nanocomposite particles containing salmon calcitonin for inhalation.
Yang M; Yamamoto H; Kurashima H; Takeuchi H; Yokoyama T; Tsujimoto H; Kawashima Y
Eur J Pharm Sci; 2012 Aug; 46(5):374-80. PubMed ID: 22414702
[TBL] [Abstract][Full Text] [Related]
25. Improved absorption of salmon calcitonin by ultraflexible liposomes through intranasal delivery.
Chen M; Li XR; Zhou YX; Yang KW; Chen XW; Deng Q; Liu Y; Ren LJ
Peptides; 2009 Jul; 30(7):1288-95. PubMed ID: 19540427
[TBL] [Abstract][Full Text] [Related]
26. Rapid intradermal delivery of liquid formulations using a hollow microstructured array.
Burton SA; Ng CY; Simmers R; Moeckly C; Brandwein D; Gilbert T; Johnson N; Brown K; Alston T; Prochnow G; Siebenaler K; Hansen K
Pharm Res; 2011 Jan; 28(1):31-40. PubMed ID: 20582455
[TBL] [Abstract][Full Text] [Related]
27. Development of a drug-coated microneedle array and its application for transdermal delivery of interferon alpha.
Kusamori K; Katsumi H; Sakai R; Hayashi R; Hirai Y; Tanaka Y; Hitomi K; Quan YS; Kamiyama F; Yamada K; Sumida S; Kishi K; Hashiba K; Sakane T; Yamamoto A
Biofabrication; 2016 Jan; 8(1):015006. PubMed ID: 26756832
[TBL] [Abstract][Full Text] [Related]
28. Microneedles for transdermal drug delivery: a minireview.
Vandervoort J; Ludwig A
Front Biosci; 2008 Jan; 13():1711-5. PubMed ID: 17981662
[TBL] [Abstract][Full Text] [Related]
29. Composite Separable Microneedles for Transdermal Delivery and Controlled Release of Salmon Calcitonin for Osteoporosis Therapy.
Li Y; Ju XJ; Fu H; Zhou CH; Gao Y; Wang J; Xie R; Wang W; Liu Z; Chu LY
ACS Appl Mater Interfaces; 2023 Jan; 15(1):638-650. PubMed ID: 36576723
[TBL] [Abstract][Full Text] [Related]
30. Controlled transdermal delivery of model drug compounds by MEMS microneedle array.
Xie Y; Xu B; Gao Y
Nanomedicine; 2005 Jun; 1(2):184-90. PubMed ID: 17292077
[TBL] [Abstract][Full Text] [Related]
31. PK/PD modelling of comb-shaped PEGylated salmon calcitonin conjugates of differing molecular weights.
Ryan SM; Frías JM; Wang X; Sayers CT; Haddleton DM; Brayden DJ
J Control Release; 2011 Jan; 149(2):126-32. PubMed ID: 20946924
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of oral bioavailability of salmon calcitonin through chitosan-modified, dual drug-loaded nanoparticles.
Liu L; Yang H; Lou Y; Wu JY; Miao J; Lu XY; Gao JQ
Int J Pharm; 2019 Feb; 557():170-177. PubMed ID: 30597264
[TBL] [Abstract][Full Text] [Related]
33. Improvement of transdermal delivery of sumatriptan succinate using a novel self-dissolving microneedle array fabricated from sodium hyaluronate in rats.
Wu D; Quan YS; Kamiyama F; Kusamori K; Katsumi H; Sakane T; Yamamoto A
Biol Pharm Bull; 2015; 38(3):365-73. PubMed ID: 25757917
[TBL] [Abstract][Full Text] [Related]
34. Microneedle-Mediated Transdermal Delivery of Bevacizumab.
Courtenay AJ; McCrudden MTC; McAvoy KJ; McCarthy HO; Donnelly RF
Mol Pharm; 2018 Aug; 15(8):3545-3556. PubMed ID: 29996645
[TBL] [Abstract][Full Text] [Related]
35. Improved nasal absorption of salmon calcitonin by powdery formulation with N-acetyl-L-cysteine as a mucolytic agent.
Matsuyama T; Morita T; Horikiri Y; Yamahara H; Yoshino H
J Control Release; 2006 Oct; 115(2):183-8. PubMed ID: 16989920
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of HPβCD-PEG microparticles for salmon calcitonin administration via pulmonary delivery.
Tewes F; Gobbo OL; Amaro MI; Tajber L; Corrigan OI; Ehrhardt C; Healy AM
Mol Pharm; 2011 Oct; 8(5):1887-98. PubMed ID: 21882837
[TBL] [Abstract][Full Text] [Related]
37. Transdermal delivery of macromolecules using solid-state biodegradable microstructures.
Wendorf JR; Ghartey-Tagoe EB; Williams SC; Enioutina E; Singh P; Cleary GW
Pharm Res; 2011 Jan; 28(1):22-30. PubMed ID: 20535531
[TBL] [Abstract][Full Text] [Related]
38. Oral multiple w/o/w emulsion formulation of a peptide salmon calcitonin: in vitro-in vivo evaluation.
Dogru ST; Calis S; Oner F
J Clin Pharm Ther; 2000 Dec; 25(6):435-43. PubMed ID: 11123497
[TBL] [Abstract][Full Text] [Related]
39. Enhancement of nasal salmon calcitonin absorption by lauroylcarnitine chloride in rats.
Kagatani S; Shinoda T; Fukui M; Ohmura T; Hasumi S; Sonobe T
Pharm Res; 1996 May; 13(5):739-43. PubMed ID: 8860430
[TBL] [Abstract][Full Text] [Related]
40. Intrapulmonary drug delivery of salmon calcitonin.
Deftos LJ; Nolan JJ; Seely BL; Clopton PL; Cote GJ; Whitham CL; Florek LJ; Christensen TA; Hill MR
Calcif Tissue Int; 1997 Oct; 61(4):345-7. PubMed ID: 9312206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
